Reviva Pharmaceuticals Holdings, Inc.
RVPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $22,907 | $31,420 | $18,948 | $4,852 |
| G&A Expenses | $7,892 | $8,084 | $5,359 | $5,253 |
| SG&A Expenses | $7,892 | $8,084 | $5,359 | $5,253 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $30,799 | $39,504 | $24,307 | $10,105 |
| Operating Income | -$30,799 | -$39,504 | -$24,307 | -$10,105 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $900 | $260 | -$12 | $1,589 |
| Pre-Tax Income | -$29,899 | -$39,244 | -$24,319 | -$8,516 |
| Tax Expense | $20 | $17 | $21 | $6 |
| Net Income | -$29,919 | -$39,261 | -$24,339 | -$8,522 |
| % Margin | – | – | – | – |
| EPS | -0.9 | -1.65 | -1.45 | -0.58 |
| % Growth | 45.5% | -13.8% | -150% | – |
| EPS Diluted | -0.9 | -1.65 | -1.45 | -0.58 |
| Weighted Avg Shares Out | 33,147 | 23,798 | 19,516 | 14,791 |
| Weighted Avg Shares Out Dil | 33,147 | 23,798 | 19,516 | 14,791 |
| Supplemental Information | – | – | – | – |
| Interest Income | $361 | $398 | $183 | $0 |
| Interest Expense | $18 | $34 | $183 | $2 |
| Depreciation & Amortization | $30,799 | $39,504 | $195 | $1 |
| EBITDA | -$29,881 | -$39,210 | -$24,112 | -$10,105 |
| % Margin | – | – | – | – |